Monopar Therapeutics Inc
$ 59.09
-0.55%
11 Jun - close price
- Market Cap 395,881,000 USD
- Current Price $ 59.09
- High / Low $ 61.01 / 58.01
- Stock P/E N/A
- Book Value 20.59
- EPS -1.93
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -0.16 %
- 52 Week High 105.00
- 52 Week Low 29.18
About
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to developing proprietary therapies to improve clinical outcomes for cancer patients in the United States. The company is headquartered in Wilmette, Illinois.
Analyst Target Price
$112.62
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-27 | 2025-11-13 | 2025-08-12 | 2025-05-13 | 2025-03-31 | 2024-11-08 | 2024-08-09 | 2024-05-09 | 2024-03-28 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.46 | -0.61 | -0.48 | -0.35 | -0.38 | -2.75 | -0.37 | -0.5 | -0.1 | -0.12 | -0.14 | -0.16 |
| Estimated EPS | -0.8975 | -0.5123 | -0.3989 | -0.09 | -0.5667 | -0.42 | -0.48 | -0.47 | -0.12 | -0.15 | -0.17 | -0.18 |
| Surprise | 0.4375 | -0.0977 | -0.0811 | -0.26 | 0.1867 | -2.33 | 0.11 | -0.03 | 0.02 | 0.03 | 0.03 | 0.02 |
| Surprise Percentage | 48.7465% | -19.0709% | -20.3309% | -288.8889% | 32.9451% | -554.7619% | 22.9167% | -6.383% | 16.6667% | 20% | 17.6471% | 11.1111% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MNPR
2026-06-10 05:22:00
This article analyzes momentum shifts for Monopar Therapeutics Inc. (NASDAQ: MNPR), highlighting a weak near-term sentiment despite potential long-term strength. It presents AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes a multi-timeframe signal breakdown, indicating divergent sentiment across different horizons.
2026-06-04 05:08:40
H.C. Wainwright has reiterated its Buy rating for Monopar Therapeutics (MNPR.US) and maintained a target price of $105 per share.
2026-06-03 18:38:51
This article provides a brief overview of current analyst ratings for Monopar Therapeutics (MNPR.US). The forecast for the company's stock is presented with a range of $101 to $105.
2026-06-03 17:09:50
Piper Sandler has reiterated its Buy rating on Monopar Therapeutics (MNPR.US) and maintained its target price of $101. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
2026-06-03 03:39:50
Lake Street maintained a Buy rating on Monopar Therapeutics Inc. (MNPR) with a price target of $103.00, according to an analyst report. This follows a similar Buy rating by Morgan Stanley with a $115.00 price target. The company recently reported a GAAP net loss of $3.89 million for the quarter ending March 31.
2026-05-30 04:09:19
This article provides a real-time signal analysis for Monopar Therapeutics Inc. (NASDAQ: MNPR), indicating a strong overweight bias across all time horizons. It details several AI-generated trading strategies including long, momentum breakout, and short setups, along with multi-timeframe signal analysis for support and resistance levels. The report highlights an exceptional short setup with a favorable risk-reward ratio.
